The EV-202 trial is an open-label phase II study (NCT04225117) evaluating ORR in previously treated locally advanced/metastatic malignant solid tumours, including HR-positive and HER2-negative BC and TNBC. The gene discussed is ERBB2; the disease is breast cancer.